Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells 128,127 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the completion of the transaction, the chief executive officer now directly owns 97,687 shares in the company, valued at $5,692,221.49. This trade represents a 56.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Friday, January 31st, Andrew Dudum sold 100,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.22, for a total value of $3,522,000.00.
• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.08, for a total value of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.00, for a total transaction of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total transaction of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.38, for a total transaction of $1,118,663.94.

Hims & Hers Health Trading Down 26.1 %

HIMS traded down $17.32 on Friday, hitting $49.10. 87,881,723 shares of the company were exchanged, compared to its average volume of 17,758,602. The firm has a 50-day moving average price of $34.66 and a two-hundred day moving average price of $25.48. The company has a market cap of $10.73 billion, a price-to-earnings ratio of 111.58 and a beta of 1.35. Hims & Hers Health, Inc. has a twelve month low of $9.25 and a twelve month high of $72.98.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. SlateStone Wealth LLC lifted its position in shares of Hims & Hers Health by 4.0% during the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock worth $257,000 after purchasing an additional 413 shares during the last quarter. Blume Capital Management Inc. lifted its holdings in Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 600 shares during the last quarter. Summit Investment Advisors Inc. boosted its position in shares of Hims & Hers Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock worth $480,000 after acquiring an additional 628 shares in the last quarter. Quest Partners LLC increased its holdings in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company's stock valued at $81,000 after acquiring an additional 807 shares during the last quarter. Finally, Harbour Investments Inc. raised its position in shares of Hims & Hers Health by 18.8% during the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock worth $127,000 after acquiring an additional 833 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on HIMS shares. Canaccord Genuity Group raised their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday. TD Cowen restated a "buy" rating and issued a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Needham & Company LLC increased their target price on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a "buy" rating in a research note on Monday, January 6th. Citigroup cut shares of Hims & Hers Health from a "neutral" rating to a "sell" rating and lifted their price target for the company from $24.00 to $25.00 in a research report on Friday, January 10th. Finally, Piper Sandler upped their price objective on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a "neutral" rating in a report on Monday, January 6th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $28.53.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.